Compare Sun Life Financial Inc. Common Stock (SLF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sun Life Financial Inc. Common Stock vs Viatris Inc — how do they compare? Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B), while Viatris Inc trades at $17.59 (market cap $19.81B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 2.2× Viatris Inc's market cap, and Sun Life Financial Inc. Common Stock pays the higher dividend (3.48%). Which is the better fit depends on your goals — on Pluang, investors hold Sun Life Financial Inc. Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| SLF | VTRS | |
|---|---|---|
Market Cap | $43.10B | $19.81B |
Volume | 448,420 | 7,547,542 |
Sector | Financials | Health |
52-Week High | $84.07 | $18.27 |
52-Week Low | $57.60 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $44.83B | $31.92B |
Dividend Yield | 3.48% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Viatris (VTRS) trades at $17.25, down 1.65% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue remains stable around $14.3B annually, though the company posted a net loss of $3.51B in 2025. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target, representing 28% upside potential.
The outlook suggests potential upside from current levels if earnings momentum continues, supported by strong cash flow generation and dividend payments. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the generic drug market. The stock appears reasonably valued with P/S of 1.36x, but the elevated P/E of 236x reflects current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
